TY - JOUR
T1 - Top Melanoma Articles from 2021 to Inform Your Cancer Practice
AU - Gershenwald, Jeffrey E.
N1 - Funding Information:
Jeffrey E. Gershenwald is supported in part by the Michael and Patricia Booker Melanoma Research Endowment, the John Skibber Endowed Professorship, the MD Anderson NIH/NCI SPORE in Melanoma (1 P50 CA221703-01A1) and associated Melanoma, Informatics, Tissue Resource, and Translational Pathology Core (MelCore), a Department of Defense Congressionally Directed Medical Research Program (DoD CDMRP) Team Science Award (CA170374), and the MD Anderson Cancer Center Melanoma Moon Shots Program.
Publisher Copyright:
© 2023, Society of Surgical Oncology.
PY - 2023/10
Y1 - 2023/10
N2 - Advances in our understanding of melanoma biology and the role of immune checkpoint blockade and targeted therapy have ushered in a new and rapidly evolving era of multidisciplinary care for patients with melanoma. Based on efficacy for patients with metastatic melanoma, these systemic treatment approaches have been introduced into the adjuvant and, more recently, the neoadjuvant landscape. This report highlights the results of key clinical studies published or initially presented in 2021 that have informed our evidence-based approach to melanoma multidisciplinary care, primarily related to adjuvant and neoadjuvant approaches for patients with resectable or resected stage III or high-risk stage II melanoma and their impact on clinical care. Knowledge concerning these areas of active clinical investigation is critical for surgical oncologists who care for melanoma patients as the treatment landscape continues to evolve.
AB - Advances in our understanding of melanoma biology and the role of immune checkpoint blockade and targeted therapy have ushered in a new and rapidly evolving era of multidisciplinary care for patients with melanoma. Based on efficacy for patients with metastatic melanoma, these systemic treatment approaches have been introduced into the adjuvant and, more recently, the neoadjuvant landscape. This report highlights the results of key clinical studies published or initially presented in 2021 that have informed our evidence-based approach to melanoma multidisciplinary care, primarily related to adjuvant and neoadjuvant approaches for patients with resectable or resected stage III or high-risk stage II melanoma and their impact on clinical care. Knowledge concerning these areas of active clinical investigation is critical for surgical oncologists who care for melanoma patients as the treatment landscape continues to evolve.
UR - http://www.scopus.com/inward/record.url?scp=85165891803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165891803&partnerID=8YFLogxK
U2 - 10.1245/s10434-023-13853-1
DO - 10.1245/s10434-023-13853-1
M3 - Article
C2 - 37493893
AN - SCOPUS:85165891803
SN - 1068-9265
VL - 30
SP - 6325
EP - 6331
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 11
ER -